Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, raised $20 million in a Series B financing.
Molten Ventures led the investment round, with participation from existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension.
With fresh funds, Qureight plans to further advance its 3D chest imaging platform and accelerate commercial expansion across key new therapeutic markets for lung and heart diseases.
Commenting on the funding, Dr. Muhunthan Thillai, MD, PhD, Co-founder and CEO of Qureight, said: “Expanding our 3D imaging deep learning models with our new AI laboratory will complement our existing dominance in lung fibrosis, allow us to enter new markets, and solidify our leadership position in the lung and heart imaging CRO market.”
Qureight is already serving biopharma clients, providing real-time insights and precision endpoints to accelerate clinical trials in a number of fibrotic lung diseases.